Nirma acquires majority stake in Glenmark Life Sciences
Glenmark Life Sciences Limited (GLS), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced the signing of a Master Supply Agreement (MSA) with a Japanese innovator pharmaceutical company with global presence in Europe, United States and Asia. Under the aegis of the Master Supply Agreement, Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator.
Glenmark launches triple-drug combo for type 2 diabetes
Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic diabetes drug in the American market. nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-gets-usfda-nod-to-market-generic-diabetes-drug/articleshow/102302377.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Nirma closes in on Glenmark's API arm, emerges sole contender as bid deadline ends
Glenmark Life Sciences on Friday reported a 24.5 per cent jump in its net profit to Rs 135.4 crore in the quarter that ended on June 30 as compared to Rs 108.7 crore in the same period last year.
Washing powder maker Nirma and Sekhmet vie for $731 million Glenmark Life stake: Sources
Glenmark gets USFDA nod to market generic diabetes drug